[go: up one dir, main page]

SI0922034T1 - Tetrahydroquinoline derivatives as eaa antagonists - Google Patents

Tetrahydroquinoline derivatives as eaa antagonists

Info

Publication number
SI0922034T1
SI0922034T1 SI9730404T SI9730404T SI0922034T1 SI 0922034 T1 SI0922034 T1 SI 0922034T1 SI 9730404 T SI9730404 T SI 9730404T SI 9730404 T SI9730404 T SI 9730404T SI 0922034 T1 SI0922034 T1 SI 0922034T1
Authority
SI
Slovenia
Prior art keywords
tetrahydroquinoline derivatives
eaa antagonists
eaa
antagonists
tetrahydroquinoline
Prior art date
Application number
SI9730404T
Other languages
English (en)
Slovenian (sl)
Inventor
Romano Di-Fabio
Alessandra Pasquarello
Fabio Maria Sabbatini
Original Assignee
Glaxosmithkline S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline S.P.A. filed Critical Glaxosmithkline S.P.A.
Publication of SI0922034T1 publication Critical patent/SI0922034T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9730404T 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists SI0922034T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1997/004440 WO1998007704A1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists
EP97943809A EP0922034B1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Publications (1)

Publication Number Publication Date
SI0922034T1 true SI0922034T1 (en) 2003-02-28

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730404T SI0922034T1 (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives as eaa antagonists

Country Status (34)

Country Link
US (1) US6479488B1 (xx)
EP (1) EP0922034B1 (xx)
JP (1) JP4108129B2 (xx)
KR (1) KR100552864B1 (xx)
CN (1) CN1131214C (xx)
AP (1) AP877A (xx)
AR (1) AR008296A1 (xx)
AT (1) ATE221052T1 (xx)
AU (1) AU724473B2 (xx)
BR (1) BR9711311B1 (xx)
CA (1) CA2264118C (xx)
CO (1) CO4900066A1 (xx)
CZ (1) CZ296250B6 (xx)
DE (1) DE69714265T2 (xx)
DK (1) DK0922034T3 (xx)
EA (1) EA001704B1 (xx)
ES (1) ES2181030T3 (xx)
GB (1) GB9617305D0 (xx)
HU (1) HU225797B1 (xx)
ID (1) ID18095A (xx)
IL (1) IL128141A0 (xx)
IS (1) IS4953A (xx)
MY (1) MY116952A (xx)
NO (1) NO312241B1 (xx)
NZ (1) NZ333812A (xx)
PE (1) PE107098A1 (xx)
PL (1) PL194532B1 (xx)
PT (1) PT922034E (xx)
SI (1) SI0922034T1 (xx)
TR (1) TR199900336T2 (xx)
TW (1) TW449582B (xx)
WO (1) WO1998007704A1 (xx)
YU (1) YU6799A (xx)
ZA (1) ZA977326B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
RU2292346C2 (ru) * 2001-12-28 2007-01-27 Акадиа Фармасьютикалз, Инк. Гетероциклические мускариновые агонисты и композиции, их применение и способы лечения
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
KR20050092123A (ko) * 2003-01-23 2005-09-20 아카디아 파마슈티칼스 인코포레이티드 Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
ES2324713T3 (es) * 2003-12-22 2009-08-13 Acadia Pharmaceuticals Inc. Analogos de diaril(a,d)ciclohepteno amino-sustituidos como agonistas muscarinicos y metodos de tratamiento de trastornos neuropsiquiatricos.
JP2007536216A (ja) * 2004-04-01 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
US7910751B2 (en) 2005-07-22 2011-03-22 Mochida Pharmaceutical Co., Ltd. Heterocyclidene acetamide derivative
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
US7955418B2 (en) 2005-09-12 2011-06-07 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
WO2011053874A1 (en) 2009-10-30 2011-05-05 Tandem Abela Development Group Llc Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
EP3718547A1 (en) 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029668T2 (de) * 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
DK0854867T3 (da) * 1995-09-29 2002-12-02 Glaxosmithkline Spa Tetrahydroquinoliner som NMDA-antagonister

Also Published As

Publication number Publication date
IL128141A0 (en) 1999-11-30
NO990723L (no) 1999-04-14
PL331562A1 (en) 1999-07-19
IS4953A (is) 1999-01-22
CN1131214C (zh) 2003-12-17
YU6799A (sh) 2000-03-21
ES2181030T3 (es) 2003-02-16
EA199900121A1 (ru) 1999-10-28
AU4551897A (en) 1998-03-06
JP2001508031A (ja) 2001-06-19
TR199900336T2 (xx) 1999-04-21
PL194532B1 (pl) 2007-06-29
NZ333812A (en) 2000-07-28
DE69714265D1 (de) 2002-08-29
GB9617305D0 (en) 1996-09-25
ID18095A (id) 1998-02-26
AP9901459A0 (en) 1999-03-31
CO4900066A1 (es) 2000-03-27
BR9711311B1 (pt) 2009-01-13
TW449582B (en) 2001-08-11
CA2264118A1 (en) 1998-02-26
US6479488B1 (en) 2002-11-12
AR008296A1 (es) 1999-12-29
DK0922034T3 (da) 2002-11-18
ATE221052T1 (de) 2002-08-15
PE107098A1 (es) 1999-01-15
PT922034E (pt) 2002-12-31
JP4108129B2 (ja) 2008-06-25
EP0922034A1 (en) 1999-06-16
BR9711311A (pt) 1999-08-17
NO312241B1 (no) 2002-04-15
AU724473B2 (en) 2000-09-21
WO1998007704A1 (en) 1998-02-26
CN1227544A (zh) 1999-09-01
MY116952A (en) 2004-04-30
KR100552864B1 (ko) 2006-02-20
HUP9903108A3 (en) 2004-04-28
NO990723D0 (no) 1999-02-16
EP0922034B1 (en) 2002-07-24
ZA977326B (en) 1999-02-15
CZ296250B6 (cs) 2006-02-15
KR20000068172A (ko) 2000-11-25
DE69714265T2 (de) 2003-03-06
EA001704B1 (ru) 2001-06-25
HU225797B1 (en) 2007-09-28
CZ52999A3 (cs) 1999-07-14
AP877A (en) 2000-09-27
CA2264118C (en) 2008-06-17

Similar Documents

Publication Publication Date Title
IL143782A0 (en) Quinoline derivatives
IL140346A0 (en) Quinoline derivatives
AP2000001933A0 (en) Quinoline derivatives
AP9901459A0 (en) Tetrahydroquinoline derivatives as eaa antagonists
CY2505B1 (en) Quinoline derivatives as nk3 antagonists
IL113844A0 (en) Quinoline derivatives
ZA97913B (en) Substituted quinazolines derivatives
IL132192A0 (en) Substituted 3-cyano quinolines
HUP0103634A3 (en) Quinoline derivatives
IL127432A0 (en) Substituted benzimidazole derivatives
IL140062A0 (en) Tetrahydroquinoline derivatives as glycine antagonists
GB9404378D0 (en) Quinoline derivatives
ZA954269B (en) Quinoline derivatives
GB9402275D0 (en) Quinoline derivatives
GB9413150D0 (en) Quinoline derivatives
EG24161A (en) Carbostyril derivatives
HK1018452A (en) Tetrahydroquinoline derivatives as eaa antagonists
SG53049A1 (en) 1-carba-(dethia)-cephalosporin derivatives
HU9603342D0 (en) Quinoline derivatives as leukotriene antagonists
GB9616476D0 (en) 6-aryl-(methyl-or methylidone)-quinoline derivatives as voltage-gated
SI1086093T1 (sl) Derivati tetrahidrokinolina kot antagonisti glicina
GB9711030D0 (en) Quinoline leukrotriene antagonists
GB9413937D0 (en) Quinoline derivatives
IL139301A0 (en) Quinoline derivatives
GB9402306D0 (en) Quinoline derivatives